Search

Your search keyword '"Pfisterer, Matthias"' showing total 979 results
Start Over Author "Pfisterer, Matthias"
979 results on '"Pfisterer, Matthias"'

54. Effects of percutaneous coronary interventions in silent ischemia after myocardial infraction

Author

Erne, Paul, Schoenenberger, Andreas W., Burckhardt, Dieter, Kiowski, Wolfgang, Buser, Peter T., Dubach, Paul, Resink, Therese J., and Pfisterer, Matthias

Subjects
Heart attack -- Care and treatment, Ischemia -- Care and treatment, Angioplasty -- Usage
Abstract

Long term effect of percutaneous coronary intervention (PCI) in patients with silent ischemia after myocardial infraction was studied in comparison with anti-ischemic drug therapy alone. PCI was found to be more beneficial than optimized drug therapy alone, in reducing long term risk of major cardiac events.

Published
2007

55. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents

Author

Kastrati, Adnan, Mehilli, Julinda, Pache, Jurgenv, Kaiser, Christoph, Valgimigli, Marco, Kelbaek, Henning, Menichelli, Maurizio, Sabate, Manel, Suttorp, Maarten J., Baumgart, Dietrich, Seyfarth, Melchior, Pfisterer, Matthias E., and Schomig, Albert

Subjects
Stent (Surgery) -- Usage, Blood clot -- Care and treatment, Blood clot -- Analysis, Thrombosis -- Care and treatment, Thrombosis -- Analysis, Heart attack -- Risk factors, Heart attack -- Care and treatment
Abstract

The long-term outcome of treatment with sirolimus-eluting stents, as compared with bare-metal stents is evaluated by analyzing the data obtained from randomized trials. The results have shown that the use of sirolimus-eluting stents have no significant effect on overall long-term survival and survival free of myocardial infarction, as compared with bare-metal stents, but the risk of stent thrombosis is at least as great as that observed with bare-metal stents.

Published
2007

56. Long-Term Results After Drug-Eluting Versus Bare-Metal Stent Implantation in Saphenous Vein Grafts:Randomized Controlled Trial

Author

Fahrni, Gregor, Farah, Ahmed, Engstrøm, Thomas, Galatius, Søren, Eberli, Franz, Rickenbacher, Peter, Conen, David, Mueller, Christian, Pfister, Otmar, Twerenbold, Raphael, Coslovsky, Michael, Cattaneo, Marco, Kaiser, Christoph, Mangner, Norman, Schuler, Gerhard, Pfisterer, Matthias, Möbius-Winkler, Sven, Jeger, Raban V, Fahrni, Gregor, Farah, Ahmed, Engstrøm, Thomas, Galatius, Søren, Eberli, Franz, Rickenbacher, Peter, Conen, David, Mueller, Christian, Pfister, Otmar, Twerenbold, Raphael, Coslovsky, Michael, Cattaneo, Marco, Kaiser, Christoph, Mangner, Norman, Schuler, Gerhard, Pfisterer, Matthias, Möbius-Winkler, Sven, and Jeger, Raban V

Abstract

Background Efficacy data on drug-eluting stents (DES) versus bare-metal stents (BMS) in saphenous vein grafts are controversial. We aimed to compare DES with BMS among patients undergoing saphenous vein grafts intervention regarding long-term outcome. Methods and Results In this multinational trial, patients were randomized to paclitaxel-eluting or BMS. The primary end point was major adverse cardiac events (cardiac death, nonfatal myocardial infarction, and target-vessel revascularization at 1 year. Secondary end points included major adverse cardiac events and its individual components at 5-year follow-up. One hundred seventy-three patients were included in the trial (89 DES versus 84 BMS). One-year major adverse cardiac event rates were lower in DES compared with BMS (2.2% versus 16.0%, hazard ratio, 0.14; 95% CI, 0.03-0.64, P=0.01), which was mainly driven by a reduction of subsequent myocardial infarctions and need for target-vessel revascularization. Five-year major adverse cardiac event rates remained lower in the DES compared with the BMS arm (35.5% versus 56.1%, hazard ratio, 0.40; 95% CI, 0.23-0.68, P<0.001). A landmark-analysis from 1 to 5 years revealed a persistent benefit of DES over BMS (hazard ratio, 0.33; 95% CI, 0.13-0.74, P=0.007) in terms of target-vessel revascularization. More patients in the BMS group underwent multiple target-vessel revascularization procedures throughout the study period compared with the DES group (DES 1.1% [n=1] versus BMS 9.5% [n=8], P=0.013). Enrollment was stopped before the target sample size of 240 patients was reached. Conclusions In this randomized controlled trial with prospective long-term follow-up of up to 5 years, DES showed a better efficacy than BMS with sustained benefits over time. DES may be the preferred strategy in this patient population. Registration URL: https://www.clini​caltr​ials.gov; Unique identifier: NCT00595647.

Published
2020

57. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis

Author

Stettler, Christoph, Wandel, Simon, Allemann, Sabin, Kastrati, Adnan, Morice, Marie Claude, Schömig, Albert, Pfisterer, Matthias E, Stone, Gregg W, Leon, Martin B, de Lezo, José Suarez, Goy, Jean-Jacques, Park, Seung-Jung, Sabaté, Manel, Suttorp, Maarten J, Kelbaek, Henning, Spaulding, Christian, Menichelli, Maurizio, Vermeersch, Paul, Dirksen, Maurits T, Cervinka, Pavel, Petronio, Anna Sonia, Nordmann, Alain J, Diem, Peter, Meier, Bernhard, Zwahlen, Marcel, Reichenbach, Stephan, Trelle, Sven, Windecker, Stephan, and Jüni, Peter

Published
2007
Full Text
View/download PDF

60. Anemia as independent predictor of major events in elderly patients with chronic angina

Author

Muzzarelli, Stefano and Pfisterer, Matthias

Subjects
Cardiology, Aged patients, Anemia, Heart failure, Angina pectoris, Cardiac patients, Health
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ahj.2006.06.014 Byline: Stefano Muzzarelli, Matthias Pfisterer Abstract: Anemia correlates with worse outcome in patients with heart failure, after myocardial infarction or angioplasty. Its prevalence increases with age, but the influence of anemia on outcome of elderly patients with stable symptomatic coronary artery disease (CAD) is unknown. Therefore, we assessed the impact of anemia on long-term outcome in elderly patients with CAD. Author Affiliation: Division of Cardiology, University Hospital, Basel, Switzerland Article History: Received 3 February 2006; Accepted 9 June 2006 Article Note: (footnote) The TIME study has been supported by grants from the Swiss Heart Foundation, Berne, Switzerland, and the Adumed Foundation, Zurich, Switzerland.

Published
2006

61. Use of B-type natriuretic peptide in the detection of myocardial ischemia

Author

Staub, Daniel, Nusbaumer, Charly, Zellweger, Michael J., Jonas, Nils, Wild, Damian, Pfisterer, Matthias E., Mueller-Brand, Jan, Perruchoud, Andre P., and Mueller, Christian

Subjects
Natriuretic peptides -- Analysis, Myocardial ischemia -- Diagnosis, Myocardial ischemia -- Research, Biological markers -- Analysis, Health
Published
2006

62. Management of elderly patients with congestive heart failure -- Design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)

Author

Rocca, Hans Peter Brunner-La, Buser, Peter Theo, Schindler, Ruth, Bernheim, Alain, Rickenbacher, Peter, and Pfisterer, Matthias

Subjects
Health
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ahj.2005.10.022 Byline: Hans Peter Brunner-La Rocca (a), Peter Theo Buser (a), Ruth Schindler (a), Alain Bernheim (a), Peter Rickenbacher (b), Matthias Pfisterer (a) Abstract: Little is known about the management of elderly patients with congestive heart failure (CHF) although they represent the majority of the CHF population. Therefore, the TIME-CHF study was set up (1) to evaluate the medical management of very old patients ([greater than or equal to]75 years) with CHF compared with younger patients (60-74 years), (2) to compare an intensified with a standard treatment approach, and (3) to differentiate between systolic and diastolic dysfunction (ejection fraction [less than or equal to]45% vs >45%). Author Affiliation: (a) Division of Cardiology, University Hospital Basel, Basel, Switzerland (b) Division of Cardiology, Kantonsspital Bruderholz, Bruderholz, Switzerland Article History: Received 7 July 2005; Accepted 20 October 2005 Article Note: (footnote) This study is sponsored by the Horten Foundation, Lugano, Switzerland, as well as by unrestricted grants from AstraZeneca Pharma, Menarini Pharma, Novartis Pharma, Pfizer Pharma, Servier (all Switzerland with equal contributions), Roche Diagnostics, Roche Pharma, and Merck Pharma, Switzerland.

Published
2006

63. Management of elderly patients with congestive heart failure--design of the trail of intensified versus standard Medical therapy in elderly patients with Congestive Heart Failure (TIME-CHF)

Author

Brunner-La Rocca, Hans Peter, Buser, Peter Theo, Schindler, Ruth, Bernheim, Alain, Rickenbacher, Peter, and Pfisterer, Matthias

Subjects
Aged patients -- Health aspects, Aged patients -- Care and treatment, Congestive heart failure -- Management, Therapeutics -- Research, Therapeutics -- Management, Homeopathy -- Materia medica and therapeutics, Homeopathy -- Research, Homeopathy -- Management, Company business management, Health
Published
2006

64. Long-term prognostic value of the preoperative 12-lead electrocardiogram before major noncardiac surgery in coronary artery disease

Author

Jeger, Raban V., Probst, Cecilia, Arsenic, Ruza, Lippuner, Thomas, Pfisterer, Matthias E., Seeberger, Manfred D., and Filipovic, Miodrag

Subjects
Coronary heart disease -- Care and treatment, Coronary heart disease -- Patient outcomes, Electrocardiogram -- Research, Electrocardiography -- Research, Preoperative care -- Research, Cardiac patients -- Prognosis, Heart -- Surgery, Heart -- Patient outcomes, Health
Published
2006

66. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET)

Author

Kaiser, Christoph, Brunner-La Rocca, Hans Peter, Buser, Peter T., Bonetti, Piero O., Osswald, Stefan, Linka, Andre, Bernheim, Alain, Zutter, Andreas, Zellweger, Michael, Grize, Leticia, and Pfisterer, Matthias E.

Subjects
Stent (Surgery) -- Evaluation, Stent (Surgery) -- Complications and side effects, Stent (Surgery) -- Usage
Published
2005

69. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea

Author

Mueller, Christian, Scholer, Andre, Laule-Kilian, Kirsten, Martina, Benedict, Schindler, Christian, Buser, Peter, Pfisterer, Matthias, and Perruchoud, Andre P.

Subjects
Congestive heart failure -- Care and treatment, Shortness of breath -- Care and treatment, Natriuretic peptides -- Testing
Abstract

A randomized controlled study of 452 patients with acute dyspnea was conducted. From dyspnea, B-type peptide levels are found to be relatively higher in patients with congestive heart failure than from other causes.

Published
2004

70. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes

Author

McGuire, Darren K., Newby, L. Kristin, Bhapkar, Manjushri V., Moliterno, David J., Hochman, Judith S., Klein, Werner W., Weaver, W. Douglas, Pfisterer, Matthias, Corbalan, Ramon, Dellborg, Mikael, Granger, Chrisotpher B., Van De Werf, Frans, Topol, Eric J., and Califf, Robert M.

Subjects
Diabetics -- Health aspects, Diabetics -- Research, Coronary heart disease -- Patient outcomes, Coronary heart disease -- Risk factors, Diabetes -- Complications and side effects, Diabetes -- Patient outcomes, Health
Published
2004

75. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial

Author

Pfisterer, Matthias, Buser, Peter, Osswald, Stefan, Allemann, Urs, Amann, Wolfgang, Angehrn, Walter, Eeckhout, Eric, Erne, Paul, Estlinbaum, Werner, Kuster, Gabriela, Moccetti, Tiziano, Naegeli, Barbara, and Rickenbacher, Peter

Subjects
Angina pectoris -- Care and treatment, Angina pectoris -- Patient outcomes, Transluminal angioplasty -- Evaluation, Aged patients -- Care and treatment, Coronary heart disease -- Care and treatment, Coronary heart disease -- Patient outcomes
Abstract

Coronary angioplasty may be better than drug therapy for elderly people with angina pectoris, according to a study of 282 patients. Patient outcomes and mortality rates were similar in patients treated with either angioplasty or drugs. However, patients treated with drugs were more likely to be hospitalized and to require angioplasty.

Published
2003

81. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes

Author

Tricoci, Pierluigi, Huang, Zhen, Held, Claes, Moliterno, David J., Armstrong, Paul W., Van de Werf, Frans, White, Harvey D., Aylward, Philip E., Wallentin, Lars, Chen, Edmond, Lokhnygina, Yuliya, Pei, Jinglan, Leonardi, Sergio, Rorick, Tyrus L., Kilian, Ann M., Jennings, Lisa H.K., Ambrosio, Giuseppe, Bode, Christoph, Cequier, Angel, Cornel, Jan H., Diaz, Rafael, Erkan, Aycan, Huber, Kurt, Hudson, Michael P., Jiang, Lixin, Jukema, Wouter J., Lewis, Basil S., Lincoff, Michael A., Montalescot, Gilles, Nicolau, José Carlos, Ogawa, Hisao, Pfisterer, Matthias, Prieto, Juan Carlos, Ruzyllo, Witold, Sinnaeve, Peter R., Storey, Robert F., Valgimigli, Marco, Whellan, David J., Widimsky, Petr, Strony, John, Harrington, Robert A., and Mahaffey, Kenneth W.

Published
2012
Full Text
View/download PDF

85. Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME‐CHF trial

Author

Stöhr, Robert, primary, Brandenburg, Vincent M., additional, Heine, Gunnar H., additional, Maeder, Micha T., additional, Leibundgut, Gregor, additional, Schuh, Alexander, additional, Jeker, Urs, additional, Pfisterer, Matthias, additional, Sanders‐van Wijk, Sandra, additional, and Brunner‐la Rocca, Hans‐Peter, additional

Published
2020
Full Text
View/download PDF

91. BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial

Author

Pfisterer, Matthias, Buser, Peter, Rickli, Hans, Gutmann, Marc, Erne, Paul, Rickenbacher, Peter, Vuillomenet, André, Jeker, Urs, Dubach, Paul, Beer, Hansjürg, Yoon, Se-Il, Suter, Thomas, Osterhues, Hans H., Schieber, Michael M., Hilti, Patrick, Schindler, Ruth, and Rocca, Hans-Peter Brunner-La

Published
2009

92. Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27–28 September 2007

Author

Daemen, Joost, Simoons, Maarten L., Wijns, William, Bagust, Adrian, Bos, Gert, Bowen, James M., Braunwald, Eugene, Camenzind, Edoardo, Chevalier, Bernard, DiMario, Carlo, Fajadet, Jean, Gitt, Anselm, Guagliumi, Giulio, Hillege, Hans L., James, Stefan, Jüni, Peter, Kastrati, Adnan, Kloth, Sabine, Kristensen, Steen D., Krucoff, Mitchell, Legrand, Victor, Pfisterer, Matthias, Rothman, Martin, Serruys, Patrick W., Silber, Sigmund, Steg, Philippe G., Tariah, Ibrahim, Wallentin, Lars, Windecker, Stephan W., Aimonetti, A., Allocco, D., Baczynska, A., Bagust, A., Berenger, M., Bos, G., Boam, A., Bowen, J.M., Braunwald, E., Calle, J.P., Camenzind, E., Campo, G., Carlier, S., Chevalier, B., Daemen, J., de Schepper, J., Di Bisceglie, G., DiMario, C., Dobbels, H., Fajadet, J., Farb, A., Ghislain, J.C., Gitt, A., Guagliumi, G., Hellbardt, S., Hillege, H.L., ten Hoedt, R., Isaia, C., James, S., de Jong, P., Jüni, P., Kastrati, A., Klasen, E., Kloth, S., Kristensen, S.D., Krucoff, M., Legrand, V., Lekehal, M., LeNarz, L., Ni Mhullain, F., Nagai, H., Patteet, A., Paunovic, D., Pfisterer, M., Potgieter, A., Purdy, I., Raveau-Landon, C., Rothman, M., Serruys, P.W., Silber, S., Simoons, M.L., Steg, P.G., Tariah, I., Ternstrom, S., Van Wuytswinkel, J., Waliszewski, M., Wallentin, L., Wijns, W., and Windecker, S.W.

Published
2009

95. Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial.

Author

Caobelli, Federico, Haaf, Philip, Haenny, Gianluca, Pfisterer, Matthias, and Zellweger, Michael J.

Subjects
CARDIOVASCULAR diseases risk factors, MYOCARDIAL perfusion imaging, CORONARY artery disease, PEOPLE with diabetes, PROGNOSIS, REPERFUSION, MYOCARDIAL reperfusion, BRUGADA syndrome, DRUG-eluting stents
Abstract

Background: The Basel Asymptomatic High-Risk Diabetics' Outcome Trial (BARDOT) demonstrated that asymptomatic diabetic patients with an abnormal myocardial perfusion scintigraphy (MPS) were at increased risk of major adverse cardiovascular events (MACEs) at 2-year follow-up. It remains unclear whether this finding holds true even for a longer follow-up. Methods: Four hundred patients with type 2 diabetes, neither history nor symptoms of coronary artery disease (CAD), were evaluated clinically and with MPS. Patients were followed up for 5 years. Major adverse cardiovascular events (MACEs) were defined as all-cause death, myocardial infarction, or late coronary revascularization. Results: At baseline, an abnormal MPS (SSS ≥ 4 or SDS ≥ 2) was found in 87 of 400 patients (22%). MACE within 5 years occurred in 14 patients with abnormal MPS (16.1%) and in 22 with normal scan (1.7%), p = 0.009; 15 deaths were recorded. Patients with completely normal MPS (SSS and SDS = 0) had lower rates of MACEs than patients with abnormal scans (2.5% vs. 7.0%, p = 0.032). Patients with abnormal MPS who had undergone revascularization had a lower mortality rate and a better event-free survival from MI and revascularization than patients with abnormal MPS who had either undergone medical therapy only or could not be revascularized (p = 0.002). Conclusions: MPS may have prognostic value in asymptomatic diabetic patients at high cardiovascular risk over a follow-up period of 5 years. Patients with completely normal MPS have a low event rate and may not need retesting within 5 years. Patients with an abnormal MPS have higher event rates and may benefit from a combined medical and revascularization approach. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results